Bright Minds Biosciences Inc (DRUG) FinancialsDRUGBright Minds Biosciences Inc

Evaluating the bottom line, Bright Minds Biosciences Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -13.63%, provide a clear picture of how effectively DRUG converts its operational activities into shareholder value.

In the context of the broader market, DRUG competes directly with industry leaders such as STTK and ARVN. With a market capitalization of $530.88M, it holds a significant position in the sector. When comparing efficiency, DRUG's gross margin of N/A stands against STTK's N/A and ARVN's 96.40%. Such benchmarking helps identify whether Bright Minds Biosciences Inc. is trading at a premium or discount relative to its financial performance.

The company has faced challenges with net income, reporting a loss of -10,459,627 CAD in Q2 2026 and a negative EPS of -1.09. However, its current ratio is strong at 121.97, indicating good short-term liquidity.